Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Seagen Inc.
  6. News
  7. Summary
    SGEN   US81181C1045

SEAGEN INC.

(SGEN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Wolfe Research Starts Seagen at Peer Perform With $195 Price Target

11/09/2021 | 10:23am EST


© MT Newswires 2021
All news about SEAGEN INC.
01/25Seagen Canada Announces Availability of PADCEV® to Treat Advanced Bladder Cancer
CI
01/18Seagen Reports Data From SEA-CD40 in Combination With Other Therapies in Metastatic Pan..
BU
01/18Seagen Inc. Announces Data from Phase I Clinical Trial Combining SEA-CD40
CI
01/18Morgan Stanley Adjusts Seagen Price Target to $178 From $181, Maintains Equalweight Rat..
MT
01/18Seagen to Host Conference Call and Webcast Discussion of Fourth Quarter and Full Year 2..
BU
01/14Pieris Doses First Patient in Phase 2 Gastric Cancer Trial of Cinrebafusp Alfa
MT
01/06INSIDER SELL : Seagen
MT
2021INSIDER SELL : Seagen
MT
2021European Committee Recommends Astellas Pharma's Bladder Cancer Drug for Approval
MT
2021Seagen to Present at the J.P. Morgan Healthcare Conference
BU
More news
Analyst Recommendations on SEAGEN INC.
More recommendations
Financials (USD)
Sales 2021 1 549 M - -
Net income 2021 -647 M - -
Net cash 2021 2 348 M - -
P/E ratio 2021 -34,6x
Yield 2021 -
Capitalization 22 592 M 22 592 M -
EV / Sales 2021 13,1x
EV / Sales 2022 9,40x
Nbr of Employees 2 092
Free-Float 99,3%
Chart SEAGEN INC.
Duration : Period :
Seagen Inc. Technical Analysis Chart | SGEN | US81181C1045 | MarketScreener
Technical analysis trends SEAGEN INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Last Close Price 123,55 $
Average target price 189,89 $
Spread / Average Target 53,7%
EPS Revisions
Managers and Directors
Clay B. Siegall Director & Chief Scientific Officer
Todd E. Simpson Chief Financial Officer
Vaughn B. Himes Chief Technical Officer
Roger D. Dansey Chief Medical Officer
Marc E. Lippman Independent Director
Sector and Competitors
1st jan.Capi. (M$)
SEAGEN INC.-20.08%22 875
MODERNA, INC.-39.94%61 847
LONZA GROUP AG-20.30%49 060
IQVIA HOLDINGS INC.-16.27%45 129
ICON PUBLIC LIMITED COMPANY-19.15%20 381
CELLTRION, INC.-21.21%18 444